<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although pharmacological and interventional advances have reduced the morbidity and mortality of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e>, there is an ongoing need for novel therapeutic strategies that prevent or reverse progressive ventricular remodeling following <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, the process that forms the substrate for <z:e sem="disease" ids="C0849925" disease_type="Disease or Syndrome" abbrv="">ventricular failure</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The development of cell-based therapy as a strategy to repair or regenerate injured tissue offers extraordinary promise for a powerful anti-remodeling therapy </plain></SENT>
<SENT sid="2" pm="."><plain>In this regard, the field of cell therapy has made major advancements in the past decade </plain></SENT>
<SENT sid="3" pm="."><plain>Accumulating data from preclinical studies have provided novel insights into stem cell engraftment, differentiation, and interactions with host cellular elements, as well as the effectiveness of various methods of cell delivery and accuracy of diverse imaging modalities to assess therapeutic efficacy </plain></SENT>
<SENT sid="4" pm="."><plain>These findings have in turn guided rationally designed translational clinical investigations </plain></SENT>
<SENT sid="5" pm="."><plain>Collectively, there is a growing understanding of the parameters that underlie successful cell-based approaches for improving heart structure and function in ischemic and other <z:hpo ids='HP_0001638'>cardiomyopathies</z:hpo> </plain></SENT>
</text></document>